AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. It also offers thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. In addition, the company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; and Asclera injection for treating uncomplicated spider and reticular veins of the lower extremities. Further, it provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation system; and radiofrequency ablation products for ablating solid cancerous or benign tumors. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone518-795-1400
Debt
Current Ratio2.88
Quick Ratio1.86
Price-To-Earnings
Sales & Book Value
Annual Sales$344.29 million
Price / Sales2.19
Price / Cash Flow15.05
Price / Book1.38
Profitability
Net Income$16.33 million
Net Margins5.10%
Return on Assets4.41%
Miscellaneous
Employees1,145
OptionableOptionable
AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions
What is AngioDynamics' stock symbol?
AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."
How were AngioDynamics' earnings last quarter?
AngioDynamics, Inc. (NASDAQ:ANGO) issued its quarterly earnings results on Friday, January, 4th. The medical instruments supplier reported $0.22 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.21 by $0.01. The medical instruments supplier earned $91.50 million during the quarter, compared to analysts' expectations of $89.24 million. AngioDynamics had a net margin of 5.10% and a return on equity of 5.85%. The firm's revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.16 EPS. View AngioDynamics' Earnings History.
When is AngioDynamics' next earnings date?
What guidance has AngioDynamics issued on next quarter's earnings?
AngioDynamics updated its FY19 earnings guidance on Friday, January, 4th. The company provided EPS guidance of $0.82-0.86 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.84. The company issued revenue guidance of $354-359 million, compared to the consensus revenue estimate of $356.09 million.AngioDynamics also updated its FY 2019 guidance to $0.82-0.86 EPS.
What price target have analysts set for ANGO?
3 equities research analysts have issued twelve-month target prices for AngioDynamics' stock. Their forecasts range from $16.33 to $23.00. On average, they anticipate AngioDynamics' stock price to reach $19.6650 in the next twelve months. This suggests that the stock has a possible downside of 3.1%. View Analyst Price Targets for AngioDynamics.
What is the consensus analysts' recommendation for AngioDynamics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AngioDynamics.
Has AngioDynamics been receiving favorable news coverage?
Press coverage about ANGO stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AngioDynamics earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of AngioDynamics' key competitors?
Some companies that are related to AngioDynamics include Merit Medical Systems (MMSI), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), K2M Group (KTWO), Nevro (NVRO), AtriCure (ATRC), Tactile Systems Technology (TCMD), Luminex (LMNX), Cryolife (CRY), Cardiovascular Systems (CSII) and Orthofix Medical (OFIX).
Who are AngioDynamics' key executives?
AngioDynamics' management team includes the folowing people:
- Mr. James C. Clemmer, CEO, Pres & Director (Age 55)
- Mr. Michael C. Greiner, Exec. VP & CFO (Age 46)
- Mr. David D. Helsel, Sr. VP of Global Operations and R&D (Age 55)
- Mr. Stephen A. Trowbridge, Sr. VP & Gen. Counsel (Age 45)
- Mr. Robert A. Simpson, Sr. VP & GM of Vascular Interventions and Therapies (Age 47)
Who are AngioDynamics' major shareholders?
AngioDynamics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Louisiana State Employees Retirement System (0.04%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, James C Clemmer, Jan Stern Reed and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.
Which major investors are selling AngioDynamics stock?
How do I buy shares of AngioDynamics?
Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AngioDynamics' stock price today?
One share of ANGO stock can currently be purchased for approximately $20.30.
How big of a company is AngioDynamics?
AngioDynamics has a market capitalization of $770.60 million and generates $344.29 million in revenue each year. The medical instruments supplier earns $16.33 million in net income (profit) each year or $0.74 on an earnings per share basis. AngioDynamics employs 1,145 workers across the globe.
What is AngioDynamics' official website?
How can I contact AngioDynamics?
AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]
MarketBeat Community Rating for AngioDynamics (NASDAQ ANGO)
MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
